Albert David Share Price

Albert David Limited, with its corporate operations in Kolkata, functions as a pharmaceutical company in India. The company was incorporated in 1938 and is part of the Kothari Group. Albert David manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles. The company serves domestic and international markets across Latin America, Southeast Asia, and Africa through its diversified product portfolio.

Albert David share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on production volumes of IV fluids and formulations, raw material costs including amino acids and API, domestic and export demand, and the performance of its injectables, oral solids, topical agents, and vision care segments. Albert David stock price is influenced by various factors such as earnings, regulatory approvals from health authorities, changes in drug manufacturing standards, and competition from generic drug players. In the longer run, strategies such as product portfolio expansion, entry into new therapeutic categories, and strengthening of export distribution networks affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements.

Albert David live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Albert David live price helps in observing short term price volatility and shows how a stock moves relative to the broader healthcare index. Furthermore, monitoring Albert David stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

Albert David Limited Company Fundamentals

A. Company Background

Albert David Limited was incorporated in 1938 as part of the Kothari Group and is engaged in the manufacturing and trading of pharmaceutical products . The company operates primarily in the formulations, bulk drugs, and infusion solutions segments, supplying products such as parenterals, oral and enteral agents, topical agents, and vision care products . Its manufacturing operations are based in India, with a major production facility located in Mandideep near Bhopal for disposable syringes and needles, while corporate functions are managed from its administrative offices in Kolkata, West Bengal . The company has entered into technical collaboration with Morishita Pharmaceuticals, Japan, to manufacture amino acid infusions, and with Pharma Plan, Germany, for machinery to manufacture disposable syringes and needles. Over time, the company has expanded its product range to include anti-infectives, anti-inflammatory drugs, anti-asthmatics, anti-ulcerants, laxatives, uterine tonics, and vitamin D3 supplements. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability, demand cycles in healthcare, and input cost fluctuations including amino acids and chemicals.

B. Company Product Lines

• Pharmaceutical formulations including parenterals, oral and enteral agents, topical agents, and vision care products

• Infusion solutions in both glass and polyethylene containers (large volume IV fluids)

• Bulk drugs including anti-malarial and anti-bacterial APIs

• Herbal dosage forms and plant-based medicines

• Disposable syringes and disposable needles manufactured with imported machinery from Germany

• Product brands include Placentrex range, Anaflam range, and BREAZE range for respiratory and inflammation therapy

• Anti-peptic ulcerant range including Rabeprazole and its combinations

• Anti-asthmatic range including Montelukast and its combinations

• Amino acid infusions manufactured through technical collaboration with Morishita Pharmaceuticals, Japan

• Vitamin and mineral supplements including Alamin range for nutrition

• Laxative combinations, antiviral agents, and anti-leishmaniasis (kalazar) drugs

• Anti-oxidant supplements with Omega-3 fatty acids and probiotic formulations

• Vision care products including anti-glaucoma drugs and irrigating solutions

C. Company Revenue Model

• Domestic sales of pharmaceutical formulations, infusions, and bulk drugs to hospitals, pharmacies, and distributors across India

• Export sales to international customers in Latin American, Southeast Asian, and African countries

• Institutional contracts with government healthcare facilities and large hospital chains for supply of IV fluids and injection products

• Bulk drug sales to other pharmaceutical manufacturers for use as raw material in their formulations

• Revenue from disposable syringes and needles sold through medical supply channels

• Revenue performance is primarily influenced by demand for pharmaceutical products, raw material costs (especially amino acids and chemicals), and selling price realizations in domestic and export markets, along with regulatory approvals for new products and manufacturing certifications.

D. Geographic Presence

• Manufacturing facilities located at Mandideep near Bhopal, Madhya Pradesh, for disposable syringes and needles; other production units in West Bengal for bulk drugs and formulations

• Corporate office and registered office located in Kolkata, West Bengal, at Gillander House

• Domestic distribution network across India through pharmaceutical distributors, hospital supply channels, and medical stores

• Export markets include Latin American countries, Southeast Asian nations, and various African countries serving international pharmaceutical buyers

• Technical collaboration with Japanese and German pharmaceutical companies supports manufacturing capabilities and technology transfer

E. Key Milestones

• 1938: Incorporation of Albert David Limited in Calcutta

• 1987: Rights issue to finance technical collaboration with Morishita Pharmaceuticals, Japan, for amino acid infusion manufacturing

• 1990: New bulk drug unit set up in Kalyani, West Bengal

• 1990: Rights issue to augment long-term working capital for expansion

• Technical collaboration with Pharma Plan, Germany, for manufacturing disposable syringes and needles

• 1998-99: Development of Siozole Capsules and Ferrochelate-Z-Capsules with sustained release formulation

• 2003: Launch of INTECAR, NIMERIL-T, EVICT, ALROF-50, ADLIN and SLOZIN

• 2004: Launch of Alamin-FeZ and Pansure

• 2005: Launch of SIOOXY (Anti-Oxidant with OMEGA-3 Fatty Acid)

• 2006: Launch of ALAMTN-Xtra, VERBET (antivertigo drug), and water for injection

• 2009: Expansion of Vision Care range including anti-glaucoma products

• 2010: Launch of Anaflam XP

• 2013: Launch of anti-peptic ulcerant range and anti-asthmatic range

• 2014: Launch of Alamin Liquid and Alamin RLD (L-Arginine Sachet)

• 2015: Launch of Dhup (Vit.D3), Inbalanse-Z (probiotic), and Evict-XF (laxative)

• 2017: Launch of Sioneuron M/PG capsules, Inbalanse-Z capsules, and Breaze-Fx tablet

F. Industry Perspective

The pharmaceutical manufacturing industry in India is characterized by intense competition and stringent regulatory oversight from authorities such as the Central Drugs Standard Control Organisation. The industry is highly fragmented, with numerous small and large players competing across formulations, bulk drugs, and specialty segments. Performance is closely linked to healthcare spending, disease prevalence patterns, and government health policies. Companies in this sector must manage raw material costs, regulatory compliance, and quality assurance while competing for market share in both domestic and export markets. Profitability can be volatile, particularly for smaller players lacking economies of scale, with earnings sensitivity to price controls, currency fluctuations, and competition from generic drug manufacturers. The industry also faces challenges from pricing pressure under government schemes such as the National Pharmaceutical Pricing Authority regulations . Companies in the sector must manage cyclical demand patterns and cost volatility while maintaining operational efficiency and adhering to Good Manufacturing Practices. These factors collectively influence financial performance and investor perception of firms like Albert David.

Albert David Limited Stock Market Presence: Listings & Index Representation

Albert David Limited is listed on the National Stock Exchange (NSE) under the symbol ALBERTDAVD and on the Bombay Stock Exchange (BSE) with the scrip code 524075. Albert David share price is actively traded on both exchanges. The company’s market presence is within the small-cap segment of the market . Due to its size and sector focus, Albert David stock price is generally tracked by investors interested in the pharmaceutical and healthcare industry.

Albert David Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap and BSE Healthcare indices . Albert David share price finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other pharmaceutical and healthcare companies.

Albert David Limited Stock Performance and Share Price History

Albert David share price on NSE reflects its status as a pharmaceutical formulations and infusion solutions manufacturer in India. Performance is driven by production capacity utilization, raw material cost management, domestic distribution reach, and the company’s ability to manage operational expenses. Investors compare Albert David share price today with other pharmaceutical manufacturers and generic drug producers to gauge relative performance .

These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements. Broader sector strength has also played a role in supporting Albert David share price. In addition to operational and sector-led factors, corporate actions such as the company’s historical rights issues for expansion and modernization have shaped the company’s capital structure over the long term . This shows how corporate actions can have lasting impacts on the company’s financial positioning, even within a regulated pharmaceutical framework influenced by drug pricing policies and regulatory compliance.

While short-term movements reflect events and announcements, longer-term valuation trends are visible through Albert David share price 52-week high and low, providing context beyond daily or weekly changes. Based on available data, the stock’s 52-week high stood at approximately 957.50, while the 52-week low stood at approximately 579.90 . Highs suggest stronger pharmaceutical demand and stable margins, while lows align with market corrections or sector volatility. These levels capture impacts of pharmaceutical policies, global generic drug trends, and earnings visibility, providing context for the stock’s historical performance.

Albert David’s stock performance reflects the trading behaviour of a small-cap pharmaceutical company operating within India’s drug manufacturing ecosystem. The company’s diversified portfolio across formulations, infusions, and bulk drugs has shaped its Albert David share price history . Over the past five years, the stock has shown periods of sharp gains and phases of consolidation. The stock delivered a positive annual return of approximately 72.1 percent in 2023 and 37.2 percent in 2024, while recording negative returns in 2025 of approximately 45.0 percent, 2022 of approximately 6.3 percent, and 2019 of approximately 1.5 percent . The stock underperformed the BSE Healthcare index over the one-year, three-year, and five-year periods, with a one-year return of negative 15.0 percent and a three-year return of 7.8 percent compared to the BSE Healthcare index which delivered positive 23.8 percent and 13.7 percent over the same periods . From recent periods onwards, the Albert David share price has shown a year-to-date negative return of approximately 8.8 percent .

Albert David’s stock performance over time has closely followed India’s pharmaceutical demand and global generic drug cycles. The Albert David share price showed exceptional positive momentum in 2023 with a return of approximately 72.1 percent, reflecting the post-pandemic recovery in the pharmaceutical sector and the company’s successful product diversification. However, periods of high raw material costs and competitive pressures have contributed to consolidation in Albert David stock price. The company’s profit after tax declined in the latest fiscal year due to margin pressures, which has weighed on the Albert David stock price . The company’s revenue growth has been modest in recent periods, while operational margins have compressed. These returns highlight the cyclical nature of the pharmaceutical industry.

Despite COVID-19 disruptions, Albert David shares showed resilience during the pandemic period, with the company benefiting from sustained demand for essential pharmaceutical products including IV fluids and anti-infectives. While the broader pharmaceutical sector faced challenges with supply chain disruptions and logistics, the company’s diversified product portfolio across infusion solutions, formulations, and bulk drugs helped the stock retain value. The company has over 1,800 employees and exports to Latin American, Southeast Asian, and African countries . The company has a debt-free balance sheet with minimal debt-to-equity ratio, providing financial stability.

Albert David share price has seen decreases due to several recurring reasons. A decline in export demand or a drop in formulation realizations directly impacts profitability and leads to selling pressure. Changes in government policy, such as stricter environmental regulations for pharmaceutical manufacturing or changes in drug price controls under the National Pharmaceutical Pricing Authority, can also cause the stock to fall. Furthermore, any increase in operational costs like raw material procurement or energy expenses without a matching rise in product prices squeezes the company’s margins, making the stock less attractive. Periods of global economic slowdown that affect pharmaceutical spending raise concerns about export volumes, leading to a drop in Albert David share price. Broader market sell-offs in small-cap stocks also pull the price down, regardless of the company’s individual performance. A decrease in capacity utilization or lower sales in any product category directly hurts the company’s revenue, resulting in a lower valuation for Albert David share price. The stock underperformed the BSE Healthcare index by a significant margin over the one-year period .

Albert David Limited Investor Relevance and Role in Portfolio

Albert David Limited is a holding in small-cap and pharmaceutical portfolios, offering exposure to IV fluids, pharmaceutical formulations, and bulk drug manufacturing. Inclusion in healthcare indices underscores its importance in India’s generic drug manufacturing space. The company’s long operating history since 1938, debt-free balance sheet, and diversified product portfolio across injectables, oral solids, and infusion solutions make it a consideration for long-term allocations .

Albert David share price is influenced by the company’s ownership structure. Albert David equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of approximately 62.24 percent in the company, reflecting strong internal control as part of the Kothari Group . Foreign institutional investors hold approximately 0.60 percent of the company’s shares . Domestic institutional investors, including insurance companies, hold approximately 1.66 percent of the company’s shares . The public holds the remaining stake of approximately 35.50 percent in the company. The company’s management includes Arun Kumar Kothari as Executive Chairman, with Ranadeep Bhattacharya serving as Chief Financial Officer. This investor base with stable promoter participation underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical manufacturing.

Beyond fundamentals and ownership, Albert David stock is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on production levels, export orders, and regulatory policy actions. The stock is available for trading on both the NSE and BSE, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements.

Technical indicators provide additional insight into short-term momentum shifts in the company’s stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short-term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, the stock’s price movements have shown that it is technically neutral with a score of 41.1 out of 100, indicating a mid-range performer with average quality, financial, and technical momentum. The stock’s delivery percentage of approximately 22.5 percent on a weekly basis and 30.1 percent on a monthly basis shows variations in investor holding patterns.

Based on available data, Albert David share price beta is not readily available, indicating that the stock has not been fully assessed for its correlation with broader market movements. The company’s debt-to-equity ratio remains negligible, reflecting a debt-free balance sheet. The return on equity stood at approximately 4.44 percent, while return on capital employed stood at approximately 6.36 percent. The company’s book value per share stands at approximately 717 rupees. The company’s quick ratio of approximately 2.77 and current ratio of approximately 3.40 indicate strong liquidity, suggesting a healthy near-term financial position with sufficient assets to cover liabilities. The company’s total debt to total equity ratio of approximately 3.14 percent indicates minimal financial leverage.

Overall, Albert David demonstrates a low risk financial profile with a debt-free balance sheet and stable promoter holding, with the company maintaining a comfortable liquidity position to weather sector-specific challenges. The stock’s technical positioning as a mid-range performer suggests that it has not shown extreme momentum in either direction.

Albert David Limited Sectoral Relevance and Peer Positioning

Albert David Limited sector relevance stems from its longstanding presence in the Indian pharmaceutical industry, its portfolio of injectable formulations including IV fluids in glass and polyethylene containers, amino acid infusions through technical collaboration with Morishita Pharmaceuticals, oral and enteral agents, topical agents, vision care products including anti-glaucoma drugs, and its position as a bulk drug manufacturer and disposable syringe producer, establishing it as a focused small-cap pharmaceutical provider supporting India’s healthcare delivery ecosystem . Peer comparisons with companies like Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Cipla, and Aurobindo Pharma focus on product mix, regulatory compliance, export presence, and manufacturing capabilities rather than short-term stock moves . These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of pharmaceutical demand, generic drug trends, and regulatory compliance further highlights Albert David positioning within India’s broader pharmaceutical manufacturing market.

Albert David P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from formulations, infusion solutions, and bulk drug sales. Based on available data, the current P/E ratio has shown significant variation, with figures ranging from approximately 26.92 in FY 2025 to 8.14 in FY 2024, 8.08 in FY 2023, 8.61 in FY 2022, and 9.71 in FY 2021, reflecting wide fluctuations in investor sentiment and earnings across years. The company’s profit after tax for the latest quarter stood at approximately 15 crore rupees, representing a significant year-on-year improvement. The company’s net profit margin has shown improvement in the latest fiscal year . Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a cyclical industry.

Alongside valuation, Albert David EPS provides insight into its operational performance and income generation from formulations, infusion solutions, and bulk drugs. Between earlier fiscal years, earnings per share reflected periods of strong growth followed by moderation. Based on available data, the company reported a basic EPS of approximately 14.13 in the December 2025 quarter, showing a significant increase compared to the corresponding quarter of the previous year. The TTM EPS stands at approximately 16.8 rupees. The company’s revenue for the same quarter stood at approximately 107 crore rupees, with net profit at approximately 14.13 crore rupees. More recent quarterly performance suggests that EPS has shown strong growth as the company benefited from improved product mix and operational efficiencies.

Albert David market cap highlights its position as a small-cap player within India’s pharmaceutical sector. Based on recent data, the company’s market capitalization has shown significant variation across years, with figures of approximately 3,911 crore rupees in FY 2024, 4,630 crore rupees in FY 2023, 6,139 crore rupees in FY 2022, and 2,921 crore rupees in FY 2021. The company’s market cap has fluctuated in line with investor perceptions of the company’s growth potential following the strong rally in 2023 and subsequent correction. From earlier years through more recent periods, the market cap showed an increasing trend from 2,150 crore rupees in FY 2020 to a peak of 6,139 crore rupees in FY 2022, representing growth of approximately 186 percent at the peak, followed by significant correction. This pattern reflects strong investor confidence during favorable pharmaceutical cycles followed by contraction during challenging periods impacted by increased competition and pricing pressures. This decrease mirrors the correction in the Albert David share price from its 52-week high of approximately 957.50 to recent levels around 670-690 rupees per share .

Finally, Albert David earnings trajectory demonstrates the impact of its operational execution in a competitive industry. In recent fiscal years, total income showed growth supported by the core pharmaceutical business. Based on available data, the company’s revenue for the full fiscal year stood at approximately 344.01 crore rupees, representing a slight decrease year-on-year. However, quarterly performance has shown improvement, with total income in the December 2025 quarter at approximately 107 crore rupees, up from approximately 76 crore rupees in the same quarter of the previous year, representing an increase of approximately 41 percent. Profit after tax for the same quarter stood at approximately 14.13 crore rupees, compared to approximately 3.88 crore rupees in the corresponding quarter of the previous year, showing an increase of approximately 264 percent. The company’s average capacity utilisation in the Mandideep unit increased from 34 percent to 61 percent, while the Kalyani unit capacity utilisation also increased. The company has faced headwinds from fluctuating raw material prices and increased competitive pressures. However, the company has maintained a debt-free balance sheet with strong liquidity and has consistently declared dividends. The company also announced a 1:1 bonus issue and a 100 percent dividend in 2023. These developments illustrate the cyclical nature of the pharmaceutical industry and the company’s position within this sector.

Summary

Albert David Limited operates as a pharmaceutical manufacturer producing formulations, infusion solutions, and bulk drugs for domestic and export markets. Albert David share price moves largely with pharmaceutical demand cycles, raw material costs, and broader healthcare sector conditions. Albert David stock price reflects its specific position within the small-cap pharmaceutical manufacturing space. The company’s performance aligns with the operational results of its diversified product portfolio and manufacturing capabilities.